Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia
- PMID: 16615675
- DOI: 10.1080/15563650500514558
Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia
Abstract
Background: Hydroxychloroquine (HCQ) is used for treatment of lupus erythematosus. The cardiac toxicity of HCQ has focused primarily on acute intoxication. We report a case of chronic use of HCQ associated with torsade de pointes.
Case report: A 67-year-old female presented with acquired long QT interval syndrome with a refractory ventricular arrhythmia. She was receiving chronic therapeutic doses of HCQ for the treatment of lupus erythematosus. Torsades de pointes was diagnosed in the Emergency Department (ED). After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia. After discontinuing the HCQ, the QT interval was shorter and the patient recovered after treatment with lidocaine and isoproterenol.
Conclusion: The chronic use of HCQ for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal cardiac arrhythmias.
Similar articles
-
Cardiovascular Safety of Hydroxychloroquine in US Veterans With Rheumatoid Arthritis.Arthritis Rheumatol. 2021 Sep;73(9):1589-1600. doi: 10.1002/art.41803. Epub 2021 Aug 6. Arthritis Rheumatol. 2021. PMID: 33973403
-
Evaluating the risk of QTc prolongation associated with hydroxychloroquine use with antidepressants in lupus patients with fibromyalgia.Lupus. 2021 Oct;30(11):1844-1848. doi: 10.1177/09612033211034562. Epub 2021 Aug 5. Lupus. 2021. PMID: 34353174
-
Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus.J Clin Rheumatol. 2013 Aug;19(5):286-8. doi: 10.1097/RHU.0b013e31829d5e50. J Clin Rheumatol. 2013. PMID: 23872551 No abstract available.
-
Hydroxychloroquine in systemic lupus erythematosus (SLE).Expert Opin Drug Saf. 2017 Mar;16(3):411-419. doi: 10.1080/14740338.2017.1269168. Epub 2016 Dec 14. Expert Opin Drug Saf. 2017. PMID: 27927040 Review.
-
Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: A case report and review of the published work.J Dermatol. 2018 Mar;45(3):344-348. doi: 10.1111/1346-8138.14156. Epub 2017 Dec 14. J Dermatol. 2018. PMID: 29239026 Review.
Cited by
-
QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019.Heart Rhythm O2. 2020 Aug;1(3):167-172. doi: 10.1016/j.hroo.2020.06.002. Epub 2020 Jun 11. Heart Rhythm O2. 2020. PMID: 32835316 Free PMC article.
-
Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.Int J Cardiol. 2021 Feb 1;324:242-248. doi: 10.1016/j.ijcard.2020.09.038. Epub 2020 Sep 19. Int J Cardiol. 2021. PMID: 32956782 Free PMC article.
-
Searching for COVID-19 treatments: First, do no harm.Am J Health Syst Pharm. 2020 Oct 30;77(22):1899-1905. doi: 10.1093/ajhp/zxaa257. Am J Health Syst Pharm. 2020. PMID: 32744592 Free PMC article. No abstract available.
-
Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review.Travel Med Infect Dis. 2020 May-Jun;35:101735. doi: 10.1016/j.tmaid.2020.101735. Epub 2020 May 6. Travel Med Infect Dis. 2020. PMID: 32387694 Free PMC article. Review.
-
Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic.J Diabetes. 2020 Sep;12(9):659-667. doi: 10.1111/1753-0407.13053. Epub 2020 Jun 11. J Diabetes. 2020. PMID: 32401405 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources